Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03211988Phase 2Terminated

Entinostat Neuroendocrine (NE) Tumor

Role: lead

NCT03946527Phase 2Active Not Recruiting

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

Role: lead

NCT03838692Phase 2Withdrawn

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Role: lead

All 3 trials loaded